3 Introduction/background: a novel dual incretin analog Despite historical research stating GIP did not assist in lowering blood glucose even with supratherapeutic levels, the success of GLP-1 RAs has led to the approval of a novel GLP-1/GIP RA, tirzepatide [42]
The ceramide formulation reinforces intercellular lipid matrix, preventing dehydration, reducing chapping, and supporting long-term lip comfort
With GLP-1s, the most common are nausea and vomiting, which can be obstacles to treatment, dosing, and medication adherence
The key evidence discussed here comes from animal studies [3] in which researchers isolated the glucagon-related effects from the rest of the peptide
However, the weight loss observed in the SELECT study (9.4%) was lower than that seen in previous STEP studies.23 The study design, which was not focused on obesity, may have influenced the lower-than-expected weight reduction, which did not parallel the trend in MACE reduction
Previous studies have similarly suggested a paracrine signaling between and -cells where -cell products directly regulate -cell function 35
